Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN). - Büttner T; Marinova M; Gaertner FC; Kreppel B; Fritsche L; Immanuel C; Geraths G; Kürpig S; Küppers J; Schmidt-Wolf IGH; Essler M; Ritter M; et al. (European journal of nuclear medicine and molecular imaging, 2026)